ZAI LAB LIMITED Interest Expense Nonoperating
ZAI LAB LIMITED (ZLAB) reported Interest Expense Nonoperating of $1.59 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- ZAI LAB LIMITED interest expense nonoperating for the quarter ending 2026-06-30 was $1.59M, a 25.75% increase year-over-year.
- ZAI LAB LIMITED interest expense nonoperating for the quarter ending 2026-03-31 was $1.64M, a 37.91% increase year-over-year.
- ZAI LAB LIMITED interest expense nonoperating for the quarter ending 2025-12-31 was $1.36M, a 50.55% increase year-over-year.
- ZAI LAB LIMITED interest expense nonoperating for the quarter ending 2025-09-30 was $1.40M, a 87.92% increase year-over-year.
- ZAI LAB LIMITED interest expense nonoperating for fiscal 2025 was $5.21M, a 131.10% increase from fiscal 2024.
- ZAI LAB LIMITED interest expense nonoperating for fiscal 2024 was $2.25M.
- ZAI LAB LIMITED interest expense nonoperating for fiscal 2023 was $0.00.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.59M 10-Q · filed 2026-08-06 | $3.22M 10-Q · filed 2026-08-06 | $4.58M derived: sum of 3 quarters · filed 2026-08-06 | $5.99M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.64M 10-Q · filed 2026-05-07 | $3.00M derived: sum of 2 quarters · filed 2026-05-07 | $4.40M derived: sum of 3 quarters · filed 2026-05-07 | $5.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.76M derived: sum of 2 quarters · filed 2026-02-26 | $4.02M derived: sum of 3 quarters · filed 2026-08-06 | $5.21M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.40M 10-Q · filed 2025-11-06 | $2.66M derived: sum of 2 quarters · filed 2026-08-06 | $3.85M 10-Q · filed 2025-11-06 | $4.75M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.26M 10-Q · filed 2026-08-06 | $2.45M 10-Q · filed 2026-08-06 | $3.35M derived: sum of 3 quarters · filed 2026-08-06 | $4.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.19M 10-Q · filed 2026-05-07 | $2.09M derived: sum of 2 quarters · filed 2026-05-07 | $2.84M derived: sum of 3 quarters · filed 2026-05-07 | $3.33M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $904.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.65M derived: sum of 2 quarters · filed 2026-02-26 | $2.14M derived: sum of 3 quarters · filed 2026-02-26 | $2.25M 10-K · filed 2026-02-26 |
| 2024-09-30 | $745.00K 10-Q · filed 2025-11-06 | $1.24M derived: sum of 2 quarters · filed 2025-11-06 | $1.35M 10-Q · filed 2025-11-06 | $1.35M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $492.00K 10-Q · filed 2025-08-07 | $605.00K 10-Q · filed 2025-08-07 | $605.00K derived: sum of 3 quarters · filed 2026-02-26 | $605.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $113.00K 10-Q · filed 2025-05-08 | $113.00K derived: sum of 2 quarters · filed 2026-02-26 | $113.00K derived: sum of 3 quarters · filed 2026-02-26 | $113.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |